Small molecules for reprograming anti-tumor immunity of t cells
Номер патента: EP4277980A2
Опубликовано: 22-11-2023
Автор(ы): Peng Wu, Yingqin HOU, Yujie SHI
Принадлежит: Scripps Research Institute
Опубликовано: 22-11-2023
Автор(ы): Peng Wu, Yingqin HOU, Yujie SHI
Принадлежит: Scripps Research Institute
Реферат: Provided herein are methods for expanding activated T cells to produce T cells with less differentiated status and enhanced in vivo persistence after adoptive transfer. Activated T cells suitable for the methods include, e.g., progenitor exhausted (Tim3-TCF-1+), stem memory, and central memory T cells. The invention also provides methods for identifying progenitor exhausted T cells specific to an antigen. Further, the invention provides progenitor exhausted T cells, pharmaceutical compositions, and kits as well as methods for the treatment of cancer or infection using the same.
Agents and methods to elicit anti-tumor immune response
Номер патента: US09951311B2. Автор: Hua Gu,Ihnkyung Jang,Richard Hodes,Jeffrey J. Chiang. Владелец: US Department of Health and Human Services. Дата публикации: 2018-04-24.